Literature DB >> 19573560

Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model.

Felix J Bode1, Michael Stephan, Sara Wiehager, Huu Phuc Nguyen, Maria Björkqvist, Stephan von Hörsten, Andreas Bauer, Asa Petersén.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the HD gene. Besides psychiatric, motor and cognitive symptoms, HD patients suffer from sleep disturbances. In order to screen a rat model transgenic for HD (tgHD rats) for sleep-wake cycle dysregulation, we monitored their circadian activity peaks in the present study. TgHD rats of both sexes showed hyperactivity during the dark cycle and more frequent light cycle activity peaks indicative for a disturbed sleep-wake cycle. Focusing on males at the age of 4 and 14 months, analyses of receptor levels in the hypothalamus and the basal forebrain revealed that 5-HT(2A)- and adrenergic alpha(2)-receptor densities in these regions were significantly altered in tgHD rats compared to their wild-type littermates. Adrenergic receptor densities correlated negatively with the light cycle hyperactivity peaks at later stages of the disease in male tgHD rats. Furthermore, reduced leptin levels, a feature associated with circadian misalignment, were present. Our study demonstrates that the male tgHD rat is a suitable model to investigate HD associated sleep alterations. Further studies are warranted to elucidate the role of adrenergic- and 5-HT(2A)-receptors as therapeutic targets for dysregulation of the circadian activity in HD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19573560     DOI: 10.1016/j.bbr.2009.06.031

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  13 in total

Review 1.  'The clocks that time us'--circadian rhythms in neurodegenerative disorders.

Authors:  Aleksandar Videnovic; Alpar S Lazar; Roger A Barker; Sebastiaan Overeem
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

2.  Circadian dysfunction in the Q175 model of Huntington's disease: Network analysis.

Authors:  Benjamin Smarr; Tamara Cutler; Dawn H Loh; Takashi Kudo; Dika Kuljis; Lance Kriegsfeld; Cristina A Ghiani; Christopher S Colwell
Journal:  J Neurosci Res       Date:  2019-07-29       Impact factor: 4.164

3.  Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

Authors:  Sara Valdeolivas; Carmen Navarrete; Irene Cantarero; María L Bellido; Eduardo Muñoz; Onintza Sagredo
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 4.  Circadian rhythms in neurodegenerative disorders.

Authors:  Malik Nassan; Aleksandar Videnovic
Journal:  Nat Rev Neurol       Date:  2021-11-10       Impact factor: 42.937

5.  The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease.

Authors:  Elisabeth Singer; Lilit Hunanyan; Magda M Melkonyan; Jonasz J Weber; Lusine Danielyan; Huu Phuc Nguyen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-12

6.  Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.

Authors:  Nigel I Wood; Valentina Carta; Stefan Milde; Elizabeth A Skillings; Catherine J McAllister; Y L Mabel Ang; Alasdair Duguid; Nadeev Wijesuriya; Samira Mohd Afzal; Joe X Fernandes; T W Leong; A Jennifer Morton; Jennifer Morton
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

Review 7.  Consequences of Circadian Disruption on Neurologic Health.

Authors:  Aleksandar Videnovic; Phyllis C Zee
Journal:  Sleep Med Clin       Date:  2015-09-26

8.  Circadian Abnormalities in Motor Activity in a BAC Transgenic Mouse Model of Huntington's Disease.

Authors:  Stephen Oakeshott; Fuat Balci; Igor Filippov; Carol Murphy; Russell Port; David Connor; Ahmad Paintdakhi; Joseph Lesauter; Liliana Menalled; Sylvie Ramboz; Seung Kwak; David Howland; Rae Silver; Dani Brunner
Journal:  PLoS Curr       Date:  2011-04-05

9.  Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse.

Authors:  Sofia Hult Lundh; Rana Soylu; Asa Petersén
Journal:  PLoS One       Date:  2012-12-10       Impact factor: 3.240

10.  Using Actiwatch to monitor circadian rhythm disturbance in Huntington' disease: A cautionary note.

Authors:  Jenny Townhill; Alis C Hughes; Benny Thomas; Monica E Busse; Kathy Price; Stephen B Dunnett; Michael H Hastings; Anne E Rosser
Journal:  J Neurosci Methods       Date:  2016-01-14       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.